10 results about "Vaginal dryness" patented technology

The present invention describes a composition for vaginal, preferably intravaginal, use for the prevention and treatment of vaginal conditions, with mucoadhesive, soothing, moisturizing and pH-regulating properties. By remaining adherent to the vaginal mucosa for prolonged periods, the composition according to the invention is therefore able to alleviate pain, burning and itching, often resulting from vaginal dryness, to promote the rebalancing of the vaginal bacterial flora, to restore the natural pH, to combat vaginal atrophy, vaginosis, vaginitis, to reduce local irritation of the tissues and to combat the proliferation of pathogens.

The present disclosure provides use of a probiotic composition comprising active ingredients including Lactobacillus johnsonii, Lactobacillus gasseri, Lactobacillus crispatus, and Lactobacillus jensenii in the preparation of a microbial formulation, wherein the microbial formulation is used for: improving the therapeutic effect of an additional drug for treating bacterial vaginosis in the treatment of bacterial vaginosis; improving the prognosis of bacterial vaginosis treated with an additional drug for treating bacterial vaginosis; treating, preventing, mitigating, and / or controlling the recurrence of bacterial vaginosis in a subject; treating, preventing, mitigating, and / or controlling atrophic vaginitis in a subject; improving the Nugent score of a subject; or ameliorating vaginal dryness in a subject.

This document discloses compositions comprising one or more polyglutamic acid compounds. These compositions are used to treat, improve, prevent, or alleviate symptoms of vaginal dryness and menopausal symptoms. This document also describes compositions for treating, improving, preventing, or alleviating other dry skin symptoms on the body, extremities, hands, feet, neck, or face in subjects of all ages and sexes. This document also describes topical and suppository formulations of the compositions.

The invention relates to a composition for improving vaginal dryness and relaxation and a preparation method thereof, the composition comprises a fusion protein as shown in SEQ ID NO: 4, the fusion protein RGD-Collagen-FGF2 is formed by connecting an RGD element (SEQ ID NO: 1), a human III-type collagen active fragment (SEQ ID NO: 2) and an FGF2 active fragment (SEQ ID NO: 3) through a linker to form a'retention-repair-regeneration 'synergistic network effect: RGD realizes positioning retention, Collagen constructs an ECM (extracellular matrix) scaffold, and the fusion protein is used for improving vaginal dryness and relaxation. The FGF2 activates epithelial regeneration; in a vaginal dry mouse model, local administration of the fusion protein can significantly improve vaginal epithelial thickness, ECM water content and mucoprotein expression and reduce epithelial permeability, the effect is better than that of estriol positive drugs, mucosal atrophy is reversed from a pathological mechanism for the first time, and hormone dependence risks are avoided.

The present invention relates to a pollen-based composition or an extract from a pollen-based composition, wherein the composition or extract stimulates the production of hyaluronic acid (HA). The composition or extract comprises at least glucose-6-phosphate as a substrate or precursor for hyaluronic acid (HA) production. The compositions or extracts of the present invention further comprise other small molecular weight bioactive molecules and / or compounds selected from the group comprising flavonoids, flavonols, flavones, alkaloids, aglycones, glycosides, lipids, fatty acids, amino acids, anthranilic acids and isomers thereof, spermidine and isomers thereof, a caffeoyl spermidine compound; and hydroxycinnamic acid. The invention also relates to formulations comprising a pollen-based composition or extract useful for the treatment of a variety of conditions, including skin problems and skin aging as well as symptoms of climacteric genitourinary syndrome (GSM), the symptoms of the climacteric genitourinary syndrome (GSM) include urinary incontinence, vaginal dryness, vaginal atrophy, irritation, pruritus, rhagadia, thinning, redness, inflammation and a decline in sexual desire, sexual function, sexual response and / or sexual pleasure.

To provide a therapeutic or preventive pharmaceutical drug for a disease selected from ocular dryness, vaginal dryness and oral burning syndrome.SOLUTION: According to the present invention, for example, the treatment of above disease is performed using a TRPM8 agonist selected from ethyl 3-(p-methane-3-carboxamide), (-)-isopulegol, (+)-cis and (-)-trans p-methane-3,8-diol, (-)-cubebol, icilin, 5-methyl-4-(1-pyrrolidinyl)-3-[2H]-furanone, 4,5-dimethyl-3-(1-pyrrolidinyl)-2 [5H]-furanone, 4-methyl-3-(1-pyrrolidinyl)-2[5H]-furanone, N-ethyl-p-methane-3-carboxamide, 2-isopropyl-5-methyl-cyclohexane carboxylic acid (2-hydroxy-1,1-dimethyl-ethyl acid)-amide, 2-isopropyl-5-methyl-cyclohexane carboxylic acid (4-methoxyphenyl) amide, etc.SELECTED DRAWING: None

Compositions and methods for treating one or more symptoms associated with vaginal atrophy or discomfort are disclosed. The compositions include an effective amount of one or more of the active agents selected from pectin (P), hyaluronic acid (HA), and collagen (Cg), in a pharmaceutically acceptable carrier, for vaginal delivery. The disclosed compositions are useful in treating one or more symptoms associated with vaginal atrophy. Example subjects include postmenopausal women or premenopausal women who experience these symptoms as a result of breastfeeding, intensive vaginal douching, cigarette smoking, autoimmune conditions such as Sjogren's syndrome, pathologic conditions such as diabetes, premature ovarian insufficiency, bilateral oophorectomy, ovarian failure due to radiation or arterial embolization, hypothalamic-pituitary disorders. Additionally, the disclosed compositions are useful in generally alleviating vaginal discomfort such as pH imbalance, vaginal dryness, burning, itching, vaginal discomfort, pain and burning when urinating, dyspareunia (painful sex), and spotting during intercourse.

Sexual dysfunction, including symptoms of vaginal dryness, irritation, and dyspareunia, is a highly prevalent condition with a substantial impact on women's physical, mental, and social well-being. However, the underlying mechanisms responsible for these symptoms are largely unknown, often resulting in inadequate treatment options for patients. Thus, methods to determine interactions between vaginal microbiota, metabolites, and immune proteins in women with or without these symptoms are described herein. The objective of these methods is to improve the understanding of the pathologic mechanisms contributing to poor sexual health.

The present invention relates to a pharmaceutical or nutraceutical composition, in the form of a unit dosage for oral administration, comprising collagen peptides, astragalus powder, centella asiatica extract, mononucleotides, hyaluronic acid, for use in the prevention and / or treatment of uro-gynaecological disorders selected from: genitourinary syndrome, vulvovaginal atrophy, scleroatrophic lichen, vulvovaginal itching, vulvovaginal dryness.

Disclosed herein are compositions comprising one or more polyglutamic acid compounds. The compositions are for treating, ameliorating, preventing, or reducing the symptoms of vaginal dryness and the symptoms associated with menopause. Also described herein are suppository formulations of the compositions.